{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T19:28:22Z","timestamp":1725391702008},"reference-count":31,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T00:00:00Z","timestamp":1120176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2005,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>\u03b2-<jats:sc>d<\/jats:sc>-2\u2032,3\u2032-Dideoxy-3\u2032-oxa-5-fluorocytidine (<jats:sc>d<\/jats:sc>-FDOC) is an effective inhibitor of human immunodeficiency virus 1 (HIV-1) and HIV-2, simian immunodeficiency virus, and hepatitis B virus (HBV) in vitro. The purpose of this study was to evaluate the intracellular metabolism of<jats:sc>d<\/jats:sc>-FDOC in human hepatoma (HepG2), human T-cell lymphoma (CEM), and primary human peripheral blood mononuclear (PBM) cells by using tritiated compound. By 24 h, the levels of<jats:sc>d<\/jats:sc>-FDOC-triphosphate (<jats:sc>d<\/jats:sc>-FDOC-TP) were 2.8 \u00b1 0.4, 6.7 \u00b1 2.3, and 2.0 \u00b1 0.1 pmol\/10<jats:sup>6<\/jats:sup>cells in HepG2, CEM, and primary human PBM cells, respectively. Intracellular<jats:sc>d<\/jats:sc>-FDOC-TP concentrations remained greater than the 50% inhibitory concentration for HIV-1 reverse transcriptase for up to 24 h after removal of the drug from cell cultures. In addition to<jats:sc>d<\/jats:sc>-FDOC-monophosphate (<jats:sc>d<\/jats:sc>-FDOC-MP), -diphosphate (<jats:sc>d<\/jats:sc>-FDOC-DP), and -TP,<jats:sc>d<\/jats:sc>-FDOC-DP-ethanolamine and<jats:sc>d<\/jats:sc>-FDOC-DP-choline were detected in all cell extracts as major intracellular metabolites.<jats:sc>d<\/jats:sc>-FDOC was not a substrate for<jats:italic>Escherichia coli<\/jats:italic>thymidine phosphorylase. No toxicity was observed in mice given<jats:sc>d<\/jats:sc>-FDOC intraperitoneally for 6 days up to a dose of 100 mg\/kg per day. Pharmacokinetic studies in rhesus monkeys indicated that<jats:sc>d<\/jats:sc>-FDOC has a<jats:italic>t<\/jats:italic><jats:sub>1\/2<\/jats:sub>of 2.1 h in plasma and an oral bioavailability of 38%. The nucleoside was excreted unchanged primary in the urine, and no metabolites were detected in plasma or urine. These results suggest that further safety and pharmacological studies are warranted to assess the potential of this nucleoside for the treatment of HIV- and HBV-infected individuals.<\/jats:p>","DOI":"10.1128\/aac.49.7.2589-2597.2005","type":"journal-article","created":{"date-parts":[[2005,6,25]],"date-time":"2005-06-25T02:22:50Z","timestamp":1119666170000},"page":"2589-2597","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":7,"title":["Pharmacology and Pharmacokinetics of the Antiviral Agent \u03b2-<scp>d<\/scp>-2\u2032,3\u2032-Dideoxy-3\u2032-Oxa-5-Fluorocytidine in Cells and Rhesus Monkeys"],"prefix":"10.1128","volume":"49","author":[{"given":"Brenda I.","family":"Hernandez-Santiago","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Emory School of Medicine\/Veterans Affair Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huachun","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Emory School of Medicine\/Veterans Affair Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghazia","family":"Asif","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Emory School of Medicine\/Veterans Affair Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Beltran","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Emory School of Medicine\/Veterans Affair Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuli","family":"Mao","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Georgia, Athens, Georgia 30602"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selwyn J.","family":"Hurwitz","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Emory School of Medicine\/Veterans Affair Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Grier","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Emory School of Medicine\/Veterans Affair Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harold M.","family":"McClure","sequence":"additional","affiliation":[{"name":"Yerkes National Primate Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chung K.","family":"Chu","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Georgia, Athens, Georgia 30602"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis C.","family":"Liotta","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Emory University, Decatur, Georgia 30033"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond F.","family":"Schinazi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Emory School of Medicine\/Veterans Affair Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1006\/bbrc.1993.2646","volume":"197","year":"1993","unstructured":"Arner, E. S. J., and S. Eriksson. 1993. Deoxycytidine and 2\u2032,3\u2032-dideoxycytidine metabolism in human monocytes-derived macrophages. Biochem. Biophys. Res. Commun.197:1499-1504.","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.2.560-564.2005"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.6.1922-1928.2003"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.9.1816"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2004.02.015"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.1.158-165.2001"},{"key":"e_1_3_2_8_2","unstructured":"Gabrielsson J. and D. Weiner. 1997. Pharmacokinetics and pharmacodynamic data analysis 2nd ed. Apotekarsocieteten Stockholm Sweden."},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/095632020301400105","volume":"14","year":"2003","unstructured":"Gelenziunas, R., K. Gallagher, H. Zhang, L. Bacheler, S. Garber, J.-T. Wu, G. Shi, M. J. Otto, R. F. Schinazi, and S. Erickson-Viitanen. 2003. HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor \u03b2-d-2\u2032,3\u2032-dideoxy-2\u2032,3\u2032-didehydo-5-fluorocytidine (ReversetTM). Antivir. Chem. Chemother.14:49-59.","journal-title":"Antivir. Chem. Chemother."},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/jps.2600721003","volume":"72","year":"1983","unstructured":"Gerlowski, L. E., and P. K. Jain. 1983. Physiologically based pharmacokinetic modeling; principles and applications. J. Pharm. Sci.72:1103-1127.","journal-title":"J. Pharm. Sci."},{"key":"e_1_3_2_11_2","first-page":"738","volume":"21","year":"1993","unstructured":"Hao, Z., E. E. Stowe, G. Ahluwalia, D. C. Baker, A. K. Hebbler, C. Chisena, S. M. Musser, J. A. Kelley, C.-F. Perno, D. G. Johns, and D. A. Cooney. 1993. Characterization of 2\u2032,3\u2032-dideoxycytidine diphosphocholine and 2\u2032,3\u2032-dideoxycytidine diphosphoethanolamine. Drug Metab. Dispos.21:738-744.","journal-title":"Drug Metab. Dispos."},{"key":"e_1_3_2_12_2","first-page":"53","volume":"56","year":"2002","unstructured":"Hernandez-Santiago, B., T. Beltran, S. J. Hurwitz, C. K. Chu, D. C. Liotta, and R. F. Schinazi. 2002. Cellular pharmacology of \u03b2-d-dioxolane-5-fluorocytosine in human cells. Antivir. Res.56:53.","journal-title":"Antivir. Res."},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"264","DOI":"10.2165\/00126839-200304040-00010","volume":"4","year":"2003","unstructured":"International, L. A. 2003. Troxacitabine: BCH 4556, SPD 758, Troxatyl. Drugs R. D.4:264-268.","journal-title":"Drugs R. D."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M210113200"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2004.07.016"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(96)00653-3"},{"key":"e_1_3_2_17_2","first-page":"22","volume":"2","year":"2004","unstructured":"Miller, M. D. 2004. K65R, TAMs and tenofovir. AIDS Rev.2:22-33.","journal-title":"AIDS Rev."},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/0006-2952(83)90517-8","volume":"32","year":"1983","unstructured":"Niedzwicki, J. G., M. H. el Kouni, S. H. Chu, and S. Cha. 1983. Structure-activity relationship of ligands of the pyrimidine nucleoside phosphorylases. Biochem. Pharmacol.32:399-415.","journal-title":"Biochem. Pharmacol."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.6.1230"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.annemergmed.2004.01.016","volume":"44","year":"2004","unstructured":"Rothman, R. E. 2004. Current Centers for Disease Control and Prevention guidelines for HIV counseling, testing, and referral: critical role of and a call of action for emergency physicians. Ann. Emerg. Med.44:31-42.","journal-title":"Ann. Emerg. Med."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.6.1214"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.5.1394-1401.2002"},{"key":"e_1_3_2_23_2","first-page":"S15","volume":"7","year":"2002","unstructured":"Schinazi, R. F., J. Mellors, S. Erickson, J. Mathew, U. Parikh, P. Sharma, M. Otto, Z. Yang, C. K. Chu, and D. C. Liotta. 2002. D-FDOC: a dioxolane pyrimidine nucleoside with activity against common nucleoside-resistant HIV-1. Antivir. Ther.7:S15.","journal-title":"Antivir. Ther."},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0006-2952(92)90001-Y","volume":"44","year":"1992","unstructured":"Schinazi, R. F., A. Peck, and J.-P. Sommadossi. 1992. Substrate specificity of Escherichia coli thymidine phosphorylase for pyrimidine nucleosides with anti-human immunodeficiency virus activity. Biochem. Pharmacol.44:199-204.","journal-title":"Biochem. Pharmacol."},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.2174\/1568026043388484"},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1177\/135965350400900410","volume":"9","year":"2004","unstructured":"Stuyver, L. J., T. R. McBrayer, D. Schurmann, I. Kravec, A. Beard, L. Cartee, R. F. Schinazi, A. de la Rosa, R. L. Murphy, and M. J. Otto. 2004. Potent antiviral effect of Reverset in HIV-1-infected adults following a single oral dose. Antivir. Ther.9:529-536.","journal-title":"Antivir. Ther."},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.1.244-254.2003"},{"key":"e_1_3_2_28_2","first-page":"179","volume":"28","year":"1998","unstructured":"Tennant, B. C., B. H. Baldwin, L. A. Graham, M. A. Ascenzi, W. E. Hornbuckle, P. H. Rowland, I. A. Tochkov, A. E. Yeager, H. N. Erb, J. M. Colacino, C. Lopez, J. A. Engelhardt, R. R. Bowsher, F. C. Richardson, W. Lewis, P. J. Cote, B. E. Korba, and J. L. Gerin. 1998. Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection. Hepatology28:179-191.","journal-title":"Hepatology"},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1200\/JCO.2003.03.057","volume":"21","year":"2003","unstructured":"Townsley, C. A., K. Chi, D. S. Ernst, K. Belanger, I. Tannock, G. A. Bjarnason, D. Stewart, R. Goel, J. D. Ruether, L. L. Siu, J. Jolivet, L. McIntosh, L. Seymour, and M. J. Moore. 2003. Phase II study of troxacitabine (BCH-4556) in patients with advance and\/or metastatic renal cell carcinoma: a trial of National Cancer Institute of Canada-Clinical Trials Group. J. Clin. Oncol.21:1524-1529.","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.12.6083-6092.2002"},{"key":"e_1_3_2_31_2","first-page":"618","year":"1990","unstructured":"Voet, D., and J. G. Voet. 1990. Lipid metabolism, p. 618-677. In J. Stiefel (ed.), Biochemistry. John Wiley & Sons, Inc., New York, N.Y.","journal-title":"Biochemistry"},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1016\/S0021-9258(18)69166-5","volume":"263","year":"1988","unstructured":"Yao, Z., and D. Vance. 1988. The active synthesis of phosphatidylcholine is required for a very low density lipoprotein secretion from rat hepatocytes. J. Biol. Chem.263:2998-3004.","journal-title":"J. Biol. Chem."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.49.7.2589-2597.2005","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.49.7.2589-2597.2005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T04:49:08Z","timestamp":1706330948000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.49.7.2589-2597.2005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["10.1128\/AAC.49.7.2589-2597.2005"],"URL":"https:\/\/doi.org\/10.1128\/aac.49.7.2589-2597.2005","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,7]]},"assertion":[{"value":"2004-12-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2005-03-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2005-07-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}